Dry Eye Syndrome Market Research Report- Forecast to 2027

Dry Eye Syndrome Market research report, by type (evaporative, aqueous), by diagnosis (schirmer test, eye exam), treatment (nutritional supplements, surgery), distribution channel (hospital pharmacies) end user (hospitals) -Forecast till 2027

ID: MRFR/Pharma/4139-HCR | February 2021 | Region: Global | 90 pages

Dry Eye Syndrome Market Scenario


The Dry eye syndrome market is expected to advance with an approximate CAGR of 6.6% during the forecast period.

Tears provide lubrication, limits the risks of eye infections, washes away the foreign matter, thus, are helpful in keeping the surface of the eyes smooth and clear. Dry eye syndrome is a medical condition in which eyes’ lubrication is hindered by the unavailability of tears. Under normal condition, during excessive production, tears flow into the small drainage ducts of the inner corners of the eyes, followed by draining back into the nose. Sometimes when the production of tears and drainage is not balanced, it can result into dry eye syndrome. Eye redness, sensitivity to light, watery eyes, eye fatigue are some of the common symptoms of the disease. Increasing geriatric population, rising prevalence of diseases like diabetes, rheumatoid arthritis, and others are estimated to be the major drivers for the market growth. According to the World Health Organization in 2016, approximately 422 million adults were globally affected by diabetes in 2014, as compared to 108 million in the 1980’s. Moreover, in 2014, it was estimated that the global prevalence of diabetes was estimated to be around 8.5%. Additionally, rising per capita healthcare expenditure, and changing lifestyle boosts the market. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle and low income countries are restraining the dry eye syndrome market.  

Figure 1: Global Dry Eye Syndrome Share, By Region

 Dry Eye Syndrome

Sources: WHO, Mayo Foundation for Medical Education and Research, National Health Service, National Eye Institute, Australian Institute of Health and Welfare, annual reports, press release, white paper, and company presentation

Segmentation

The global dry eye syndrome is segmented on the basis of the type, diagnosis, treatment, distribution channel and end user.

On the basis of the type, the dry eye syndrome market is segmented into evaporative dry eye syndrome aqueous dry eye syndrome, and others. On the basis of the diagnosis, the dry eye syndrome market is categorized into Schirmer test, eye exam, and others.  On the basis of the treatment, the dry eye syndrome market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment is sub-segmented into oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segments segement is sub-segmented into tetracyclines, corticosteroids, and others. The surgery segment is sub-segmented into punctal occlusion, intense pulsed light therapy, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.  On the basis of the end users, the dry eye syndrome market is segmented into hospitals, clinics, home care, and others.

Key Players in Dry Eye Syndrome Market

The key players for the dry eye syndrome market  are Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.

Research Methodology Dry Eye Syndrome Research

Sources: WHO, Mayo Foundation for Medical Education and Research, National Health Service, National Eye Institute, Australian Institute of Health and Welfare, annual reports, press release, white paper, and company presentation

Dry Eye Syndrome Market Regional Analysis

America dominates the global dry eye syndrome market. This can be attributed to the presence of a well-developed healthcare sector and a large patient population. Moreover, increasing healthcare expenditure boosts the growth of the American market. Additionally, the presence of the major market players like Johnson & Johnson Vision, Auven therapeutics, Acadia Pharmaceutical, and others within the region fuels the growth.

Europe is the second largest dry eye syndrome market owing to increasing availability of funds for research, a well-developed healthcare sector, huge patient pool and growing geriatric population. According to the Saga in 2017, approximately 20% of people living in the U.K suffer from dry eye syndrome. Moreover, it was estimated that one in three people who age 65 or more within the region are diagnosed with this disease.

Asia Pacific is the fastest growing region for the dry eye syndrome market due to the presence of economies like India, China, Australia, and others. Moreover, huge patient population, rising healthcare expenditure boosts the market growth. According to the Australian Institute of Health and Welfare, the total Australian health expenditure from 2015 to 2016 was estimated to be about USD 170.4 billion.

The Middle East & Africa has the least share in the global dry eye syndrome market due to the presence of poor economies, low per capita healthcare expenditure, stringent government policies, especially within the African region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure by the developed economies like Dubai, Kuwait, Dubai, and others.

Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government And Private Laboratories

  • Research And Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023: 6.6%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered

  • Increasing geriatric population
  • Rising prevalence of diseases like diabetes, rheumatoid arthritis

    		•
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.)
      Key Market Opportunities

  • Rising per capita healthcare expenditure
  • Changing lifestyle

    •   Key Market Drivers

  • Increasing geriatric population
  • Rising prevalence of diseases like diabetes, rheumatoid arthritis, and others



    • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The outlook of the global dry eye syndrome market looks flourishingly growing.

    The global dry eye syndrome market is projected to grow at approximately 6.6% CAGR during forecast period (2017-2023).

    Supportive government initiatives and funding.

    North America holds the largest share in the global dry eye syndrome market followed by Europe and Asia Pacific, respectively.

    SORIN Group (Europe), LEPU MEDICAL (UK), MEDICO S.p.A. (Europe), Abbott. (US), Medtronic (US), Boston Scientific Corporation (US), OSCOR Inc. (US), and BIOTRONIK (Germany), are some of the major players operating in the dry eye syndrome market.

    TABLE OF CONTENT


    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Dry Eye Syndrome Market, by Type

    6.1 Introduction

    6.2 Evaporative Dry Eye Syndrome

    Market Estimates & Forecast, 2020 – 2027

    6.3 Aqueous Dry Eye Syndrome

    Market Estimates & Forecast, 2020 – 2027

    Chapter 7. Global Dry Eye Syndrome Market, by Diagnosis

    7.1 Introduction

    7.2 Schirmer Test

    Market Estimates & Forecast, 2020 – 2027

    7.3 Eye Exam

    Market Estimates & Forecast, 2020 – 2027

    7.4 Others

    Chapter 8. Global Dry Eye Syndrome Market, by Treatment

    8.1 Introduction

    8.2 Nutritional Supplements

    Market Estimates & Forecast, 2020 – 2027

    8.3 Serum Eye Drops

    Market Estimates & Forecast, 2020 – 2027

    8.4 Lubricant Eye Drops

    Market Estimates & Forecast, 2020 – 2027

    8.4.1 Oily Tear Eye Drops

    8.4.2 Ointments

    8.4.3 Preservative-Free drops

    8.4.4 Others

    8.5 Anti-Inflammatory Drugs Segments

    Market Estimates & Forecast, 2020 – 2027

    8.5.1 Tetracyclines

    8.5.2 Corticosteroids

    8.5.3 Others

    8.6 Surgery

    Market Estimates & Forecast, 2020 – 2027

    8.6.1 Punctal Occlusion

    8.6.2 Intense Pulsed Light Therapy

    8.6.3 Others

    8.7 Others

    Chapter 9 Global Dry Eye Syndrome Market, by Distribution Channel

    9.1 Introduction

    9.2 Hospital pharmacies

    Market Estimates & Forecast, 2020 – 2027

    9.3 Retail pharmacies

    Market Estimates & Forecast, 2020 – 2027

    9.4 Online Pharmacies

    Market Estimates & Forecast, 2020 – 2027

    9.5 Others

    Chapter 10 Global Dry Eye Syndrome Market, by End User

    10.1 Introduction

    10.2 Hospitals

    Market Estimates & Forecast, 2020 – 2027

    10.3 Clinics

    Market Estimates & Forecast, 2020 – 2027

    10.4 Home Care

    Market Estimates & Forecast, 2020 – 2027

    10.5 Others

    Chapter 11. Global Dry Eye Syndrome Market, by Region

    11.1 Introduction

    11.2 America

    11.2.1 North America

    11.2.1.1 U.S.

    11.2.1.2 Canada

    11.2.2 South America

    11.3 Europe

    11.3.1 Western Europe

    11.3.1.1 Germany

    11.3.1.2 France

    11.3.1.3 Italy

    11.3.1.4 Spain

    11.3.1.5 U.K

    11.3.1.6 Rest of Western Europe

    11.3.2 Eastern Europe

    11.4 Asia Pacific

    11.4.1 Japan

    11.4.2 China

    11.4.3 India

    11.4.4 Australia

    11.4.5 Republic of Korea

    11.4.6 Rest of Asia Pacific

    11.5 The Middle East & Africa

    11.5.1 United Arab Emirates

    11.5.2 Saudi Arabia

    11.5.3 Oman

    11.5.4 Kuwait

    11.5.5 Qatar

    11.5.6 Rest of the The Middle East & Africa

    Chapter 12 Company Landscape

    12.1 Introduction

    12.2 Market Share Analysis

    12.3 Key Development & Strategies

    12.3.1 Key Developments

    Chapter 13 Company Profiles

    13.1 Allergan

    13.1.1 Company Overview

    13.1.2 Product Overview

    13.1.3 Financials

    13.1.4 Key Developments

    13.1.5 SWOT Analysis

    13.2 Novartis AG

    13.2.1 Company Overview

    13.2.2 Product Overview

    13.2.3 Financial Overview

    13.2.4 Key Developments

    13.2.5 SWOT Analysis

    13.3 Otsuka Pharmaceutical Co. Ltd.

    13.3.1 Company Overview

    13.3.2 Product Overview

    13.3.3 Financial Overview

    13.3.4 Key Development

    13.3.5 SWOT Analysis

    13.4 Valent Pharmaceuticals

    13.4.1 Company Overview

    13.4.2 Product/Business Segment Overview

    13.4.3 Financial Overview

    13.4.4 Key Development

    13.4.5 SWOT Analysis

    13.5 Johnson and Johnson Vision

    13.5.1 Company Overview

    13.5.2 Product Overview

    13.5.3 Financial overview

    13.5.4 Key Developments

    13.5.5 SWOT Analysis

    13.6 Acadia Pharmaceutical

    13.6.1 Company Overview

    13.6.2 Product Overview

    13.6.3 Financial Overview

    13.6.4 Key Developments

    13.6.5 SWOT Analysis

    13.7 Allostera Pharma

    13.7.1 Overview

    13.7.2 Product Overview

    13.7.3 Financials

    13.7.4 Key Developments

    13.7.5 SWOT Analysis

    13.8 I-Med Pharma Inc.

    13.8.1 Overview

    13.8.2 Product Overview

    13.8.3 Financials

    13.8.4 Key Developments

    13.8.5 SWOT Analysis

    13.9 Santen Pharmaceuticals Co. Ltd.

    13.9.1 Overview

    13.9.2 Product Overview

    13.9.3 Financials

    13.9.4 Key Developments

    13.9.5 SWOT Analysis

    13.10 AFT pharmaceuticals

    13.10.1 Overview

    13.10.2 Product Overview

    13.10.3 Financials

    13.10.4 Key Developments

    13.10.5 SWOT Analysis

    13.11 Novaliq GmBh

    13.11.1 Overview

    13.11.2 Product Overview

    13.11.3 Financials

    13.11.4 Key Developments

    13.11.5 SWOT Analysis

    13.12 Auven therapeutics

    13.12.1 Overview

    13.12.2 Product Overview

    13.12.3 Financials

    13.12.4 Key Developments

    13.12.5 SWOT Analysis

    13.13 Others

    Chapter 14 MRFR Conclusion

    14.1 Key Findings

    14.1.1 From CEO’s View Point

    14.1.2 Unmet Needs of the Market

    14.2 Key Companies to Watch

    14.3 Prediction of Dry Eye Syndrome Industry

    Chapter 15 Appendix

    LIST OF TABLES

    Table 1 Dry Eye Syndrome Industry Synopsis, 2020 – 2027

    Table 2 Global Dry Eye Syndrome Market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Global Dry Eye Syndrome Market by Region, 2020 – 2027, (USD Million)

    Table 4 Global Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

    Table 5 Global Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 6 Global Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 7 Global Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 8 Global Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 9 North America Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

    Table 10 North America Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 11 North America Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 12 North America Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 13 North America Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 14 US Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

    Table 15 US Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 16 US Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 17 US Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 18 US Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 19 Canada Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

    Table 20 Canada Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 21 Canada Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 22 Canada Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 23 Canada Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 24 South America Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

    Table 25 South America Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 26 South America Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 27 South America Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 28 South America Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 29 Europe Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

    Table 30 Europe Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 31 Europe Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 32 Europe Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 33 Europe Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 34 Western Dry Eye Syndrome Europe Market by Type, 2020 – 2027, (USD Million)

    Table 35 Western Europe Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 36 Western Europe Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 37 Western Europe Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 38 Western Europe Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 39 Eastern Europe Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

    Table 40 Eastern Europe Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 41 Eastern Europe Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 42 Eastern Europe Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 43 Eastern Europe Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 44 Asia Pacific Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

    Table 45 Asia Pacific Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 46 Asia Pacific Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 47 Asia Pacific Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 48 Asia Pacific Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    Table 49 The Middle East & Africa Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

    Table 50 The Middle East & Africa Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

    Table 51 The Middle East & Africa Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

    Table 52 The Middle East & Africa Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 53 The Middle East & Africa Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Dry Eye Syndrome Market

    Figure 3 Segmentation Market Dynamics for Global Dry Eye Syndrome Market

    Figure 4 Global Dry Eye Syndrome Market Share, by Type 2020

    Figure 5 Global Dry Eye Syndrome Market Share, by Diagnosis 2020

    Figure 6 Global Dry Eye Syndrome Market Share, by Treatment 2020

    Figure 7 Global Dry Eye Syndrome Market Share, by Distribution Channel 2020

    Figure 8 Global Dry Eye Syndrome Market Share, by End User, 2020

    Figure 9 Global Dry Eye Syndrome Market Share, by Region, 2020

    Figure 10 North America Dry Eye Syndrome Market Share, by Country, 2020

    Figure 11 Europe Dry Eye Syndrome Market Share, by Country, 2020

    Figure 12 Asia Pacific Dry Eye Syndrome Market Share, by Country, 2020

    Figure 13 The Middle East & Africa Dry Eye Syndrome Market Share, by Country, 2020

    Figure 14 Global Dry Eye Syndrome Market: Company Share Analysis, 2020 (%)

    Figure 15 Allergan: Key Financials

    Figure 16 Allergan: Segmental Revenue

    Figure 17 Allergan: Geographical Revenue

    Figure 18 Novartis AG: Key Financials

    Figure 19 Novartis AG: Segmental Revenue

    Figure 20 Novartis AG: Geographical Revenue

    Figure 21 Otsuka Pharmaceutical Co. Ltd.: Key Financials

    Figure 22 Otsuka Pharmaceutical Co. Ltd.: Segmental Revenue

    Figure 23 Otsuka Pharmaceutical Co. Ltd.: Geographical Revenue

    Figure 24 Valent Pharmaceuticals: Key Financials

    Figure 25 Valent Pharmaceuticals: Segmental Revenue

    Figure 26 Valent Pharmaceuticals: Geographical Revenue

    Figure 27 Johnson and Johnson Vision: Key Financials

    Figure 28 Johnson and Johnson Vision: Segmental Revenue

    Figure 29 Johnson and Johnson Vision: Geographical Revenue

    Figure 30 Acadia Pharmaceutical: Key Financials

    Figure 31 Acadia Pharmaceutical: Segmental Revenue

    Figure 32 Acadia Pharmaceutical: Geographical Revenue

    Figure 33 Allostera Pharma: Key Financials

    Figure 34 Allostera Pharma: Segmental Revenue

    Figure 35 Allostera Pharma: Geographical Revenue

    Figure 36 I-Med Pharma Inc.: Key Financials

    Figure 37 I-Med Pharma Inc.: Segmental Revenue

    Figure 38 I-Med Pharma Inc.: Geographical Revenue

    Figure 39 Santen Pharmaceuticals Co. Ltd.: Key Financials

    Figure 40 Santen Pharmaceuticals Co. Ltd.: Segmental Revenue

    Figure 41 Santen Pharmaceuticals Co. Ltd.: Geographical Revenue

    Figure 42 AFT pharmaceuticals: Key Financials

    Figure 43 AFT pharmaceuticals: Segmental Revenue

    Figure 44 AFT pharmaceuticals: Geographical Revenue

    Figure 45 Novaliq GmBh: Key Financials

    Figure 46 Novaliq GmBh: Segmental Revenue

    Figure 47 Novaliq GmBh: Geographical Revenue

    Figure 48 Auven therapeutics: Key Financials

    Figure 49 Auven therapeutics: Segmental Revenue

    Figure 50 Auven therapeutics: Geographical Revenue